ROSSARI BIOTECH LIMITED

During the earnings conference call held on July 20, 2026, management reported that Rossari Biotech Limited achieved its highest ever quarterly revenue and EBITDA for Q1 FY27, with consolidated revenue growing 28% year-over-year. The growth was attributed to strong domestic performance and international expansion. Management highlighted the importance of innovation, noting the ramp-up of a new R&D center and the launch of a Fibre Chemicals Division to enhance their textile specialty chemicals portfolio. The company also reported a 21% increase in export revenue. Despite challenges in the institutional and consumer segments, management expressed confidence in improving margins through portfolio rationalization and operational efficiency. EBITDA for the quarter was Rs. 80.6 crore, with margins at 11.6%. Management emphasized ongoing efforts to optimize asset utilization and enhance cash flows, aiming for sustainable growth and improved profitability.

Management highlighted strong revenue growth and strategic initiatives to enhance operational efficiency.